(USTR.gov)
Theraclone Sciences Inc., a drug discovery and development company in Seattle, Washington, said today it agreed to a multi-year research and development collaboration with the global pharmaceutical company Pfizer. The deal involves use of Theraclone’s I-STAR technology to discover monoclonal antibodies against up to four targets in the areas of infectious disease and cancer.
The company says I-STAR screens and identifies human antibodies to pathogenic agents and endogenous therapeutic targets, which can quickly test the function of tens of thousands of natural human antibodies and find those with exceptional biologic activity. Theraclone and Pfizer will identify reactive antibodies directed against up to two infectious disease targets and up to two cancer targets.
Under the deal, Pfizer will receive an exclusive license to any therapeutic antibodies discovered from the collaboration, and will be responsible for preclinical and clinical development of the antibodies. Theraclone is eligible to receive royalties on sales of any developed products and up to $632 million in research funding and payments for meeting discovery, development, regulatory, and commercialization milestones. The amounts of the royalties was not disclosed.
* * *
RSS - Posts
You must be logged in to post a comment.